Expectations and preferences of patients with primary and relapsed ovarian cancer to maintenance therapy: A NOGGO/ENGOT-ov22 and GCIG survey (Expression IV)

International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
Irena RohrJalid Sehouli

Abstract

Maintenance therapy induces remission and prolongs disease free interval in primary and recurrent ovarian disease. For the treatment decision making process, aspects of quality of life and patients' preferences are crucial, despite the fact that scientific data are lacking. Therefore, we conducted this European-wide study in patients with ovarian cancer. A 25 item questionnaire was provided to ovarian cancer patients via the internet or as a paper version in 10 European countries (Austria, Belgium, France, Germany, Italy, Romania, Slovenia, Finland, Turkey, and Spain). Data recorded were demographics, tumor stage, therapy after firstline and recurrent disease, preferences for administration, and expectations concerning maintenance therapy. Overall, 1954 patients participated from September 2013 to March 2016; 42% had recurrent disease. Most patients (98%) with primary epithelial ovarian cancer underwent surgery followed by chemotherapy (91%). Almost one-third of participants (29%) were receiving maintenance therapy whereas 45% had only heard of it. For 70% of patients with primary epithelial ovarian cancer, they heard about maintenance therapy from their doctor, 10% heard about maintenance therapy from other patients, and 8% fr...Continue Reading

References

Feb 3, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G Oskay-OzcelikJ Sehouli
Apr 29, 2014·Lancet·Gordon C JaysonJonathan A Ledermann
Jan 9, 2015·Cancer Metastasis Reviews·Maurie Markman
Apr 9, 2016·International Immunology·Junzo HamanishiIkuo Konishi
Oct 9, 2016·The New England Journal of Medicine·Mansoor R MirzaUNKNOWN ENGOT-OV16/NOVA Investigators
Jan 6, 2017·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Mar 17, 2017·Expert Opinion on Pharmacotherapy·Yada KanjanapanAmit M Oza
Mar 23, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A KaramUNKNOWN participants of the 5th Ovarian Cancer Consensus Conference
Jun 12, 2017·Gynecologic Oncology·UNKNOWN PEBC’s Ovarian Oncology Guidelines Group
Sep 22, 2017·Expert Opinion on Pharmacotherapy·Cecilia OrbegosoSusana Banerjee
Dec 10, 2017·Oncotarget·Jung-Min Lee, James L Gulley
Feb 13, 2018·Clinical Oncology : a Journal of the Royal College of Radiologists·J VentrigliaS Pignata
Mar 22, 2018·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Haihong WangGuiling Li
Sep 2, 2019·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Esra UrkmezMurat Gultekin

❮ Previous
Next ❯

Citations

Feb 23, 2021·Gynecologic Oncology·Jean-Emmanuel KurtzUNKNOWN Gynecologic Cancer InterGroup (GCIG) symptom benefit committee

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.